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Abstract
Whole genome sequencing (WGS) can be a cost-effective and efficient means of
diagnosis for some children, but it also raises a number of ethical concerns. One
such concern is how researchers derive and communicate results from WGS,
including future requests for further analysis of stored sequences. The purpose of this
paper is to think about what is at stake, and for whom, in any solution that is
developed to deal with such requests. To accomplish this task, this paper will utilize
stakeholder theory, a common method used in business ethics. Several scenarios
that connect stakeholder concerns and WGS will also posited and analyzed. This
paper concludes by developing criteria composed of a series of questions that
researchers can answer in order to more effectively address requests for further
analysis of stored sequences.
Whole genome sequencing (WGS) can clearly improve diagnosis and treatment of
children in some cases (Soden et al. 2014), but it also raises a number of ethical con-
cerns. One prominent ethical issue is how to manage the incidental findings that occur
whenever a child’s entire genome is sequenced (Berg et al. 2013). The American
College of Medical Genetics recommended that certain findings be returned regardless
of whether they were the results for which the testing was undertaken or whether par-
ents requested those results. By contrast, the American Academy of Pediatrics recom-
mended that only test results that would result in a change in clinical management
during childhood should be reported (Green et al. 2013). Other scholars suggest estab-
lishing procedural approaches for making decisions, rather than specifying that any
particular findings be returned or withheld (Koenig 2014).
One way to avoid the need to deal with most incidental findings is by only examining
genes that have a high likelihood of being associated with a child’s clinical condition.
As described in Saunders et al. (2012), this approach is a part of on-going research in-
vestigating the clinical utility of WGS for sick newborns in a neonatal intensive care
unit. Current sequencing technology allows results to be available in less than 48 h,
though the interpretation of sequencing results could take longer. In order to increase
the clinical and economic efficiency of sequencing, geneticists may analyze only those
portions of the genome that have a high likelihood—based on prior studies—of being
associated with the particular symptoms of the newborn. Though the entire genome is
sequenced, the sequence is filtered so that only those variants related to a newborn’s
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symptoms are fully analyzed and returned to the treating physician. This approach only
generates information about specific genes and as such it is less likely than a more
comprehensive analysis of the genome to reveal unsought information.
This approach will not avoid every incidental finding since there may be some inci-
dental findings in the specific genes that are analyzed. But it will decrease the number
of such findings. It will not, however, eliminate the need for difficult ethical choices. In-
stead, it will raise a new set of important questions regarding when and how researcher
ought to communicate any remaining results of a WGS.
Every newborn that undergoes WGS will have their entire genome sequence stored.
In addition, both parents’ genomes are sequenced and stored in order to investigate de
novo mutations. While the information in these stored gene sequences may be inciden-
tal to a child’s current illness, it may yield information that is important to the child’s
future health. It is, therefore, likely that, in some cases, parents or physicians will
request further analysis of a child’s genome. These requests could potentially run the
gamut from those intimately connected to the child’s welfare to those based on curios-
ity. Geneticists and pediatricians will have to decide whether every such request should
be honored or, if not, to articulate criteria by which such requests should be evaluated.
Answers to questions have implications for any use of WGS as a clinical tool.
The purpose of this paper is to propose limited theoretical criteria in order to think
about what is at stake, and for whom, in any solution that is developed to deal with
these complex questions. Because these questions extend beyond WGS or healthcare
management, I will develop these criteria by using stakeholder theory—a method that
is often used in business ethics to understand the issues that arise when conflicting loy-
alties and interest groups create management challenges.
Stakeholder theory
Edward Freeman’s book, Strategic Management: A Stakeholder Approach (1984), de-
fines a stakeholder as “any group or individual who can affect or is affected by the
achievement of the organization’s objectives” (pg. 46). Stakeholders for an organization
could include its customers, employees, suppliers, regulators, critics and competitors. A
stakeholder approach to strategic management seeks the serious inclusion of these vari-
ous stakeholders’ values and interests into the everyday workings of organizations.
Within stakeholder theory, an organization “can be viewed as a set of interdependent
relationships among primary stakeholders” (Hillman and Keim 2001, pg. 127), or as the
place where ongoing voluntary agreements or contracts between stakeholders and an
organization’s managers intertwine (Freeman and Phillips 2002). Stakeholder theorists
argue that an organization’s success depends on how well it manages its relationships
with these key groups (Phillips et al. 2007).
A central admonition of stakeholder theory is that managers in organizations need to
attend to the interests of individuals and groups who can either assist or obstruct an
organization’s objectives (Phillips et al. 2007). In other words, an organization’s success
is dependent on how well it manages its relationship with the key groups that can affect
its purposes (Freeman and Phillips 2002). Stakeholder theory sees management as being
morally responsible to all stakeholders “because business actions harm or benefit vari-
ous stakeholders, or because stakeholders have rights, or because stakeholders should
be part of the processes which meaningfully affect their lives” (Gilmartin and Freeman
Thornock Life Sciences, Society and Policy  (2016) 12:4 Page 2 of 7
2002, pg. 56). Stakeholder theory does not, however, make it incumbent on managers
to treat each stakeholder equally or require managers to take from one group of stake-
holders and give to another (Freeman and Phillips 2002). Instead, stakeholder theory is
simply stating that it is practically and ethically advantageous for a manager in an
organization to take into account the groups and individuals affected or who can affect
the organization’s goals and purposes (Freeman et al. 2004).
Stakeholder theorists have developed several steps for accounting for the values
and preferences of stakeholders (Parmar et al. 2010). First, managers need to
recognize that it is counterproductive to separate “ethical” aspects of decisions or
policies from “business” aspects (Gilmartin and Freeman 2002). There is a tendency
for managers to analyze actions such as acquisitions, mergers, transactions, and
payments as if they are somehow devoid of any ethical or human dimensions—that
they are strictly business. Stakeholder theorists consider this separation fallacious
because both ethics and business are concerned with creating something of value to indi-
viduals (Freeman and Moutchnik 2013; Gilmartin and Freeman 2002). A principal task of
stakeholder theory is to pragmatically and logically find ways to stitch “business” and
“ethics” back together (Freeman et al. 2004). This project extends across the spectrum of
business ventures, including those involved in healthcare (Gilmartin and Freeman 2002).
Stakeholder theory looks to place creating value for human beings at the forefront of
all business considerations (Freeman et al. 2010).
Second, managers need to determine the purpose of the firm by “articulat[ing] the
shared sense of the value [an organization] create[s], and what brings its core stake-
holders together” (Freeman et al. 2004, pg. 364). An organization’s purpose goes beyond
just solvency and includes creating value for individuals. Each organization must have a
moral vision that reflects where it has been, where it ought to go, and what choices and
actions are necessary to get there (Freeman 2010).
Third, managers need to recognize which stakeholders are key to the organiza-
tion’s overall purpose. These key stakeholders are those individuals and groups
toward whom the organization has distinct duties such as contractual responsibil-
ities or other “direct moral obligation toward their well-being” (Phillips et al. 2007,
pg. 489).
Finally, managers need to decide how to allocate the organization’s goods and
resources. This involves asking a series of questions including: how does the
organization and its managers interact with stakeholders; what values, social
issues, and stakeholder expectations is the organization ready to meet now; when
might the organization be ready to act on a stakeholder’s desire; and how
should the organization go about fulfilling a stakeholder’s desire (Freeman 2010;
Minoja 2012).
These steps of stakeholder management may be especially helpful in times in
which the desires of one party conflict with those of other parties or with the
goals of the firm. Instead of forming a zero-sum-game logic, in which one party
loses so another can gain, managers can place stakeholder desires into the larger
context of the firm, so that if a desire must be denied or delayed it is in the
long-term benefit of all stakeholders (Gilmartin and Freeman 2002). Stakeholder
management can assist organizations achieve their overarching goals while still
responding to specific stakeholder needs and desires.
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Stakeholder theory and genomics
It is at this level that stakeholder management may benefit research organizations con-
ducting genomic testing. Consider the following three scenarios:
(1) One year after the death of their newborn, who died despite undergoing rapid
WGS, the deceased newborn’s parents request that the newborn’s sequence and
their own sequences be fully analyzed, including variants for child and adult-
onset diseases, with the complete results being returned to them for family
planning purposes.
(2) One year after undergoing rapid WGS, which was able to determine a
diagnosis that saved the newborn’s life, the infant’s pediatrician requests that
the rest of the stored sequence be analyzed, including variants for child and
adult-onset diseases, with the complete results being returned to the doctor
(3) One year after undergoing rapid WGS, which was able to determine a diagnosis
that saved the newborn’s life, the infant’s pediatrician requests that certain portions
of the stored sequence be analyzed and returned to the doctor in order to possibly
explain some chronic symptoms the infant is currently experiencing.
Determining which request, if any, should be honored requires researchers to develop
criteria that not only justify why certain requests should be fulfilled, but also why other
requests were not. Stakeholder management strategies may aid in the development of
such a criteria.
In the case of Soden et al. (2012), stakeholders should have input in decisions regard-
ing the use of stored sequences. Stakeholders clearly have a continued interest in these
sequences even after they have been used for their primary purpose. Many proposals
for including stakeholders in decisions about how to use stored sequences propose that
the decisions can be made at one point in time, usually at the outset of the study. Thus,
they may ask research participants for permission to use these sequences for future re-
search. By this view, those future research projects are an integral part of the ways in
which the enterprise provides value to stakeholders. Those stakeholders need to remain
both included and invested in the project.
Researchers might be tempted to separate ethics from what they deem as purely sci-
entific or technological actions. For instance, in WGS research, it may be tempting to
see ethics as an integral component at the bookends of a study, at the beginning when
obtaining consent or at the end when returning results, but see other steps (sequen-
cing, analyzing, verification, storage) as wholly technological or scientific endeavors
separate from ethics. However, these actions are not devoid of ethics because they are
directly related to how researchers provide value to their stakeholders. Researchers
should not assume that the storage of sequences is merely a technological or pragmatic
necessity devoid of ethical obligations.
Researchers need to work with stakeholders to decide what type of value they are try-
ing to build and for whom they are building it. This involves asking two fundamental
questions: first, what is the purpose of gene sequencing; second, for whose benefit was
the sequencing undertaken. Answering these questions allows researchers to “articulate
the shared sense of value [they] create, and what brings [their] core stakeholders to-
gether” (Freeman et al. 2004, pg. 364).
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Saunders et al. (2012) describe the purpose of the rapid WGS research as aiding in
the diagnosis of acutely ill newborns. Specifically, the aim of sequencing is to improve
clinical outcomes for some newborns and to do so in a timely and cost-effective man-
ner. Therefore, narrowing the analysis of sequences to only those variants linked with
the infant’s symptoms is not just a tricky means of avoiding incidental findings. It is a
necessary step to allow such testing to meet its primary goals in a timely and cost-
effective way. The aim of this research is also deeply humanistic: by trying to find better
ways to treat a critically ill newborn, researchers are providing a glimmer of hope in an
otherwise desperate situation. But, the storage of sequences is done for more than just
this primary goal and may aid in other research goals. Stakeholders must buy into and
support those other goals or else they may become alienated from the entire project.
A next step in stakeholder management is to identify the individuals and groups who
stand to benefit from WGS. There are numerous stakeholders for this rapid WGS re-
search and include regulators, lab personal and hospital staff, public health authorities,
device manufacturers and others. But the key stakeholders, in the case of Soden et al.
(2012), are the newborn, the parents and the treating physician. These researchers have
a direct duty or moral obligation toward each of these primary stakeholders because
these stakeholders are intimately tied with the diagnostic and clinical aims of rapid
WGS research. Because the gene sequences are being retained, these primary stake-
holders continue to have a vested interest in the way the sequences are used even after
the original obligations have been met.
Research funders, such as the NIH, may or may not be included in these key stake-
holders depending on the stipulations of the research protocol and grant. In the case of
Soden et al. (2012), the research protocol only covered the release of WGS information
that was pertinent to the immediate care of an ill neonate. As such, the analysis of
stored sequences is supererogatory and may not be funded by the original grant. In
such instances the parents themselves are going to likely pay for the additional analysis
without the aid of third parties. Researchers could, of course, amend their existing
grants or seek new funding to pay for the analysis of stored genomes in which case they
should ensure that the requirements of an external funder do not overwhelm the needs
of other key stakeholders.
After articulating the purpose of the research and identifying primary stakeholders,
researchers need to establish certain procedures that can guide transactions between
these primary stakeholders and themselves. Researchers need to be clear about the an-
swers to a number of questions. How they will interact with these primary stakeholders
on an ongoing basis? How should they evaluate the requests of primary stakeholder’s to
use the genomic data? If they want to honor stakeholders’ requests, how should the re-
searchers go about fulfilling those requests without detracting from other goals?
(Minoja 2012; Freeman 2010). Answers to these questions will allow researchers to
build a strategy that will allow research to continue toward its stated purposes while
still allowing them to respond to new requests made by certain primary research
stakeholders.
After such an exercise, researchers should be better equipped to address the scenarios
presented earlier. For the rapid WGS, researchers may be justified in dismissing a re-
quest made by solely by parents (e.g., scenario 1). Though parents are primary stake-
holders, rapid WGS is being investigated as a clinical tool, not as a direct-to-consumer
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product. Researchers have yet to establish procedures for working directly with parents,
making this type of expansion premature and inappropriate.
Since the protocol for rapid WGS was built around using the treating physician as a
liaison between the researchers and the parents, researchers are better suited to follow
a similar format to address requests for further analysis. In addition, since rapid WGS
is specifically being investigated as an aid in diagnosis, physician requests that exceed
this aim (e.g., scenario 2) should also be rejected. Similar to requests coming directly
from parents, the research protocols for rapid WGS are simply not suited for returning
such a wide range of genomic results. Therefore, requests for further analysis made by
a treating physician for a diagnostic purpose (e.g., scenario 3) are those most fitting for
this rapid WGS research protocol.
In deciding to fulfill some requests while ignoring others, researchers should not
pit the desires of one group of stakeholders over those of other groups. Instead, re-
searchers should aim to find ways that can harmonize primary stakeholders’ desires
with the overall purpose of the research. For example, they might encourage par-
ents to enlist the help of a physician to act as a liaison between them and the re-
searchers. In addition, researchers may not be able to fulfill certain requests right
now, such as using WGS for family planning; however, researchers can still work with pri-
mary stakeholders to determine a timetable in which their request for family planning
analysis could be addressed. Finally, researchers need to be transparent as possible regard-
ing why certain requests are being honors while other are not. Openly discussing how
these decisions are made can help to build trust and avoid alienation.
The criteria for deciding which requests for further analysis ought to be considered should
grow organically and pragmatically from current research practice. In this way, researchers
and research stakeholders work together toward the benefit of all. Over taxing researchers
and straining protocols not only puts current research efforts at risk, it also seriously under-
mines the researchers’ ability to fulfill any additional requests for further analysis.
Conclusions
Drawing from stakeholder theory, this paper developed a series of questions that re-
searchers can ask when determining whether to fulfill the request of a primary research
stakeholder. These questions include: what is the purpose of the research, for whose
benefit was the research undertaken, does a primary stakeholder’s request fit within the
goals of the research, when might the researchers be ready to act on the request, and
how should the researchers go about fulfilling the request. While this paper applied
these questions specifically to rapid WGS research, they can assist researchers conduct-
ing a variety of different research protocols address the changing needs of stakeholders.
Establishing such a criteria before requests are made will be a great asset to researchers
who may face evolving needs and desires of research stakeholders.
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